02/01/2026
Recent research is introducing a new way to approach cancer immunotherapy — by reprogramming immune cells directly inside the tumor.
Scientists have developed a nanoparticle-based therapy that delivers mRNA into tumor-associated macrophages, one of the most abundant immune cells within the tumor microenvironment. These macrophages are normally suppressed by the tumor and lose their ability to attack cancer cells.
Using lipid nanoparticles, the therapy induces these macrophages to express CAR (chimeric antigen receptor) proteins in vivo, effectively turning them into CAR-macrophages without removing them from the patient’s body.
Once reprogrammed, these immune cells regain their anti-tumor activity, directly attacking cancer cells and stimulating broader immune responses within the tumor environment.
In preclinical models, this strategy significantly slowed tumor growth and activated systemic anti-cancer immunity.
The key implication is conceptual as much as technical: instead of engineering immune cells outside the body and reinfusing them, it may be possible to reprogram immune function in place, inside the tumor itself.
This approach could simplify immunotherapy workflows and open new directions for targeting the tumor microenvironment.
If this topic aligns with your interests in cancer biology or immunotherapy, feel free to share it with others engaged in science-driven research and discussion.